Langenbeck's Archives of Surgery

, Volume 393, Issue 3, pp 289–296

PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas

Authors

    • Department of General SurgeryFriedrich-Alexander-University of Erlangen-Nuremberg
    • Department of Otolaryngology/Head and Neck Surgery, College of Physicians and SurgeonsColumbia University
  • Wanglong Qiu
    • Department of Otolaryngology/Head and Neck Surgery, College of Physicians and SurgeonsColumbia University
  • Helen E. Remotti
    • Department of Pathology, College of Physicians and SurgeonsColumbia University
  • Werner Hohenberger
    • Department of General SurgeryFriedrich-Alexander-University of Erlangen-Nuremberg
  • Gloria H. Su
    • Department of Otolaryngology/Head and Neck Surgery, College of Physicians and SurgeonsColumbia University
    • Department of Pathology, College of Physicians and SurgeonsColumbia University
Original Article

DOI: 10.1007/s00423-008-0285-7

Cite this article as:
Schönleben, F., Qiu, W., Remotti, H.E. et al. Langenbecks Arch Surg (2008) 393: 289. doi:10.1007/s00423-008-0285-7

Abstract

Background and aims

Recent studies have reported high frequencies of somatic mutations in the phosphoinositide-3-kinase catalytic-α (PIK3CA) gene in various human tumors. Three hot-spot mutations in the exons 9 and 20 have been proven to activate the Akt signalling pathway. The Raf/MEK/ERK (mitogen-activated protein kinase) signal transduction is an important mediator of a number of cellular fates including growth, proliferation, and survival. The BRAF gene is activated by oncogenic RAS, leading to cooperative effects in cells responding to growth factor signals. Here we evaluate the mutational status of PIK3CA, KRAS, and BRAF in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMNC) of the pancreas.

Materials and methods

Exons 1, 4, 5, 6, 7, 9, 12, 18, and 20 of PIK3CA, exons 1 of KRAS, and exons 5, 11, and 15 of BRAF were analyzed in 36 IPMN/IPMC and two mucinous cystadenoma specimens by direct genomic DNA sequencing.

Results

We identified four somatic missense mutations of PIK3CA within the 36 IPMN/IPMC specimens (11%). One of the four mutations, H1047R, has been previously reported to be a hot-spot mutation. Furthermore, we found 17 (47%) KRAS mutations in exon 1 and one missense mutation (2.7%) in exon 15 of BRAF.

Conclusion

This data is the first report of PIK3CA mutation in pancreatic cancer and it appears to be the first oncogene to be mutated in IPMN/IPMC but not in conventional ductal adenocarcinoma of the pancreas. Our data provide evidence that PIK3CA and BRAF contribute to the tumorigenesis of IPMN/IPMC, but at a lower frequency than KRAS.

Keywords

IPMN IPMC Pancreas PIK3CA KRAS BRAF Mutation

Copyright information

© Springer-Verlag 2008